Christine Gebski - Feb 24, 2022 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Role
SVP, Filtration & Chromatography
Signature
/s/ Kimberly Brown (Attorney in Fact)
Stock symbol
RGEN
Transactions as of
Feb 24, 2022
Transactions value $
-$34,247
Form type
4
Date filed
2/28/2022, 06:09 PM
Previous filing
Feb 22, 2022
Next filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGEN Common Stock Award $0 +2.12K +6.33% $0.00 35.7K Feb 24, 2022 Direct F1
transaction RGEN Common Stock Tax liability -$34.2K -181 -0.51% $189.21 35.5K Feb 24, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGEN Stock Option (Right to Buy) Award $0 +2.72K $0.00 2.72K Feb 24, 2022 Common Stock 2.72K $189.21 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ms. Gebski was awarded 2,124 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2 Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.
F3 One third of the stock options will vest and become exercisable annually on February 24, 2023, February 24, 2024 and February 24, 2025.

Remarks:

SVP, Filtration & Chromatography